Trailing-twelve-month (TTM) revenue is $978.38 Million with a year-over-year growth of +30.90%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $227,813,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-07 |
| Q4 FY2025Period ended 2025-12-31 | $247,060,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-27 |
| Q1 FY2026Period ended 2026-03-31 | $237,462,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q2 FY2026Period ended 2026-06-30 | $266,044,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $978,379,000 |
Current P/S: $1,619,159,494 market capitalization ÷ $978,379,000 TTM revenue = 1.65x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:55:21.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $266.04M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:55:48.634Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Generics, Established Brands, and Other | N/A | N/A | $275M | $105M | N/A | N/A |
| Other | N/A | $2M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| C | $6M | N/A | N/A | N/A | N/A | N/A |
| Canada | N/A | $4M | $4M |
$978.38M
$978.38 Million
+30.90%
vs. $747.42M a year ago (TTM)
+35.61%
5 Year compound annual growth rate
1 Year
+30.90%
3 Year
+34.57%
5 Year
+35.61%
10 Year
+26.97%
15 Year
+70.31%
20 Year
+46.95%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $883.37M | +$268.99M | +43.78% |
| 2024 | $614.38M | +$127.56M | +26.20% |
| 2023 | $486.82M | +$170.43M | +53.87% |
| 2022 | $316.38M | +$100.25M | +46.38% |
| 2021 | $216.14M | +$7.66M | +3.67% |
| 2020 |
TTM Growth
+30.90%
3-Year CAGR
+34.57%
5-Year CAGR
+35.61%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:55:48.634Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| N/A |
| Other Revenues | $783,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Product development services | N/A | $1M | N/A | N/A | N/A | N/A |
|---|
| Product Development Services | $2M | N/A | N/A | N/A | N/A | N/A |
|---|
| Rare Disease | N/A | N/A | $42M | $269M | N/A | N/A |
|---|
| Royalties from licensing agreements | N/A | $12M | N/A | N/A | N/A | N/A |
|---|
| Royalties From Licensing Agreements | $1M | N/A | N/A | N/A | N/A | N/A |
|---|
| Sales of branded pharmaceutical products | N/A | $48M | N/A | N/A | N/A | N/A |
|---|
| Sales Of Branded Pharmaceutical Products | $48M | N/A | N/A | N/A | N/A | N/A |
|---|
| Sales of contract manufactured products | N/A | $4M | N/A | N/A | N/A | N/A |
|---|
| Sales Of Contract Manufactured Products | $7M | N/A | N/A | N/A | N/A | N/A |
|---|
| Sales of Established Brands | N/A | N/A | N/A | N/A | $65M | $61M |
|---|
| Sales of generic pharmaceutical products | N/A | $144M | N/A | N/A | N/A | N/A |
|---|
| Sales Of Generic Pharmaceutical Products | $147M | N/A | N/A | N/A | N/A | N/A |
|---|
| Sales of rare disease pharmaceutical products | N/A | N/A | N/A | $112M | $230M | $423M |
|---|
| Total Sales of Generics and Other | N/A | N/A | N/A | N/A | $320M | $399M |
|---|
| $565,000 |
| N/A |
| N/A |
| Non-US | N/A | N/A | N/A | N/A | $9M | $31M |
|---|
| U | $203M | N/A | N/A | N/A | N/A | N/A |
|---|
| United States | N/A | $212M | $312M | $486M | N/A | N/A |
|---|
| UNITED STATES | N/A | N/A | N/A | N/A | $605M | $852M |
|---|
| $208.47M |
| +$1.93M |
| +0.93% |
| 2019 | $206.55M | +$4.97M | +2.47% |
| 2018 | $201.58M | +$24.73M | +13.99% |
| 2017 | $176.84M | +$48.22M | +37.49% |
| 2016 | $128.62M | +$52.30M | +68.53% |
